Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Arrhythmias

  Free Subscription


Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 46 articles:
HTML format



Single Articles


    June 2021
  1. CHARAFEDDINE K, Zakka P, Dargham BB, Abdulhai F, et al
    Potential Biomarkers in Atrial Fibrillation: Insight into their Clinical Significance.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98188.
    PubMed     Abstract available


  2. SKORNOVA I, Samos M, Bolek T, Kamenistakova A, et al
    Direct oral anticoagulants plasma levels in atrial fibrillation patients at the time of bleeding: a pilot prospective study.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98186.
    PubMed     Abstract available


    March 2021
  3. HEIDEMANN J, Tanislav C, Kostev K
    (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients with Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98230.
    PubMed     Abstract available


    December 2020
  4. CORDERO A, Ferreiro JL, Bertomeu-Gonzalez V, Rodriguez-Manero M, et al
    Direct oral anticoagulants vs. vitamin K antagonist after percutaneous coronary interventions in patients with atrial fibrillation: a metanalysis of cardiac ischemic events.
    J Cardiovasc Pharmacol. 2020;Publish Ahead of Print.
    PubMed     Abstract available


  5. HELENIAK Z, Papuga-Szela E, Krzysztof P, Anetta U, et al
    Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    J Cardiovasc Pharmacol. 2020;76:671-677.
    PubMed     Abstract available


    November 2020
  6. RIGOPOULOS AG, Kalogeropoulos AS, Tsoporis JN, Sakadakis EA, et al
    Heat shock protein 70 is associated with cardioversion outcome and recurrence of symptomatic recent onset atrial fibrillation in hypertensive patients.
    J Cardiovasc Pharmacol. 2020 Nov 24. doi: 10.1097/FJC.0000000000000962.
    PubMed     Abstract available


  7. NORDBECK P, Hu K
    The trend is your friend: DOACs as standard anticoagulants for patients with atrial fibrillation undergoing percutaneous coronary interventions.
    J Cardiovasc Pharmacol. 2020 Nov 3. doi: 10.1097/FJC.0000000000000950.
    PubMed    


  8. BURASHNIKOV A
    Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
    J Cardiovasc Pharmacol. 2020;76:492-505.
    PubMed     Abstract available


    October 2020
  9. HENRY M, Wosnitza M, Thate-Waschke IM, Bauersachs R, et al
    A Country-Based Comparison of Atrial Fibrillation Patient Preferences for Oral Anticoagulation: An Evaluation of Discrete Choice Experiments in five different Countries.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000936.
    PubMed     Abstract available


  10. LEE ZX, Ang E, Lim XT, Arain SJ, et al
    Association of Risk of Dementia with Direct Oral Anticoagulants versus Warfarin use in Patients with Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000925.
    PubMed     Abstract available


  11. PATTI G, Haas S
    Non-vitamin K antagonist oral anticoagulants and factors influencing the ischaemic and bleeding risk in elderly patients with atrial fibrillation: a review of current evidence.
    J Cardiovasc Pharmacol. 2020 Oct 9. doi: 10.1097/FJC.0000000000000927.
    PubMed     Abstract available


    August 2020
  12. NORDBECK P, Hu K
    Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19.
    J Cardiovasc Pharmacol. 2020;76:123-124.
    PubMed    


    July 2020
  13. CHU Y, Yang Q, Ren L, Yu S, et al
    Late sodium current in atrial cardiomyocytes contributes to the induced and spontaneous atrial fibrillation in rabbit hearts.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000883.
    PubMed     Abstract available


  14. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available


    May 2020
  15. BURASHNIKOV A, Barajas-Martinez H, Hu D, Robinson VM, et al
    The SK Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation via Atrial-selective Inhibition of Sodium Channel Activity.
    J Cardiovasc Pharmacol. 2020 May 20. doi: 10.1097/FJC.0000000000000855.
    PubMed     Abstract available


  16. RUSSO V, Rago A, Carbone A, Bottino R, et al
    Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications.
    J Cardiovasc Pharmacol. 2020 May 18. doi: 10.1097/FJC.0000000000000854.
    PubMed     Abstract available


    March 2020
  17. MA W, Guo X, Wang Q, Sun G, et al
    Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2020 Mar 26. doi: 10.1097/FJC.0000000000000832.
    PubMed     Abstract available


    February 2020
  18. WANG S, Li B, Li X, Wu L, et al
    Low-intensity ultrasound modulation may prevent myocardial infarction induced sympathetic neural activation and ventricular arrhythmia.
    J Cardiovasc Pharmacol. 2020 Feb 17. doi: 10.1097/FJC.0000000000000810.
    PubMed     Abstract available


  19. VERRIER RL, Belardinelli L
    Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2020 Feb 5. doi: 10.1097/FJC.0000000000000804.
    PubMed     Abstract available


    January 2020
  20. ZHOU D, Yang K, Hu J, Shi J, et al
    Noncoding RNAs in Atrial Fibrillation: Current Status and Prospect.
    J Cardiovasc Pharmacol. 2020;75:10-17.
    PubMed     Abstract available


  21. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available


  22. HENDRICKS AK, Nei SD, Greason KL, Scott RA, et al
    Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series.
    J Cardiovasc Pharmacol. 2020;75:41-44.
    PubMed     Abstract available


    December 2019
  23. SCHNIERER M, Samos M, Bolek T, Skornova I, et al
    The effect of PPI withdrawal on dabigatran etexilate plasma levels in patients with atrial fibrillation: a washout study.
    J Cardiovasc Pharmacol. 2019 Dec 30. doi: 10.1097/FJC.0000000000000791.
    PubMed     Abstract available


  24. MELILLO E, Carbone A, Rago A, Papa AA, et al
    Update on Direct oral anticoagulants in atrial fibrillation patients undergoing cardiac interventional procedures: from clinical trials to real-world evidence.
    J Cardiovasc Pharmacol. 2019 Dec 12. doi: 10.1097/FJC.0000000000000786.
    PubMed     Abstract available


    November 2019
  25. MARUM AA, Silva BA, Bortolotto AL, Pedreira GC, et al
    Pulmonary Delivery of Metoprolol Reduces Ventricular Rate during Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm.
    J Cardiovasc Pharmacol. 2019 Nov 25. doi: 10.1097/FJC.0000000000000780.
    PubMed     Abstract available


  26. WANG C, Yu S, Bao Q, Qiang W, et al
    Circulating Mesencephalic Astrocyte-derived Neurotrophic Factor Negatively Correlates with Atrial Apoptosis in Human Chronic Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2019 Nov 25. doi: 10.1097/FJC.0000000000000781.
    PubMed     Abstract available


    September 2019
  27. DOMEK M, Gumprecht J, Mazurek M, Chao TF, et al
    Should we judge stroke risk by static or dynamic risk scores? A focus on the dynamic nature of stroke and bleeding risks in patients with atrial fibrillation.
    J Cardiovasc Pharmacol. 2019 Sep 14. doi: 10.1097/FJC.0000000000000750.
    PubMed     Abstract available


  28. YAMAJI H, Higashiya S, Murakami T, Hina K, et al
    Effects of Oral Anticoagulants on Patients With Atrial Fibrillation Aged 90 Years and Older: Comparison Among Direct Oral Anticoagulant, Warfarin Anticoagulant, and Nonanticoagulation.
    J Cardiovasc Pharmacol. 2019;74:246-254.
    PubMed     Abstract available


    July 2019
  29. YAMAJI H, Higashiya S, Murakami T, Hina K, et al
    Effects of oral anticoagulants on >/=90-year-old atrial fibrillation patients: comparison among direct oral anticoagulant, warfarin anticoagulant, and non-anticoagulation.
    J Cardiovasc Pharmacol. 2019 Jul 22. doi: 10.1097/FJC.0000000000000703.
    PubMed     Abstract available


  30. MISHRA A, Singh M, Acker WW, Kamboj S, et al
    Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    J Cardiovasc Pharmacol. 2019 Jul 11. doi: 10.1097/FJC.0000000000000697.
    PubMed     Abstract available


    February 2019
  31. RUSSO V, Carbone A, Rago A, Golino P, et al
    Direct Oral Anticoagulants in octogenarians with atrial fibrillation: it's never too late.
    J Cardiovasc Pharmacol. 2019 Feb 26. doi: 10.1097/FJC.0000000000000661.
    PubMed     Abstract available


  32. SCHUPP T, Behnes M, Weiss C, Nienaber C, et al
    Prognostic Impact of Angiotensin Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and ICD Therapies.
    J Cardiovasc Pharmacol. 2019 Feb 8. doi: 10.1097/FJC.0000000000000659.
    PubMed     Abstract available


    January 2019
  33. YI F, Hou W, Zhou C, Yin Y, et al
    Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-Analysis of Safety and efficacy1.
    J Cardiovasc Pharmacol. 2019 Jan 25. doi: 10.1097/FJC.0000000000000654.
    PubMed     Abstract available


    December 2018
  34. GIANNOPOULOS G, Vrachatis D, Kossyvakis C, Angelidis C, et al
    Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2018;72:285-290.
    PubMed     Abstract available


    June 2018
  35. JANION-SADOWSKA A, Papuga-Szela E, Lukaszuk R, Chrapek M, et al
    Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia.
    J Cardiovasc Pharmacol. 2018 Jun 27. doi: 10.1097/FJC.0000000000000607.
    PubMed     Abstract available


    May 2018
  36. CHANG PC, Lu YY, Lee HL, Lin SF, et al
    Paradoxical Effects of Sodium-Calcium Exchanger Inhibition on Torsade de Pointes and Early Afterdepolarization in a Heart Failure Rabbit Model.
    J Cardiovasc Pharmacol. 2018 May 3. doi: 10.1097/FJC.0000000000000598.
    PubMed     Abstract available


    March 2018
  37. CHENG W, Liu W, Li B, Li D, et al
    Relations of Anticoagulant Therapy with Cognitive Impairment among Patients with Atrial Fibrillation: A Meta-Analysis and Systematic Review.
    J Cardiovasc Pharmacol. 2018 Mar 2. doi: 10.1097/FJC.0000000000000575.
    PubMed     Abstract available


    February 2018
  38. ISHIZAKA T, Yoshimatsu Y, Maeda Y, Chiba K, et al
    Inotropic Effects of Nicorandil on Cardiac Contractility Assessed by Left Ventricular Pressure-Volume Relationship Analyses in Anesthetized Monkeys.
    J Cardiovasc Pharmacol. 2018;71:76-81.
    PubMed     Abstract available


    October 2017
  39. CARSTENSEN H, Kjaer L, Haugaard MM, Flethoj M, et al
    Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses.
    J Cardiovasc Pharmacol. 2017 Oct 25. doi: 10.1097/FJC.0000000000000541.
    PubMed     Abstract available


  40. CHOI J, Kim J, Shim JH, Kim M, et al
    Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic Patients.
    J Cardiovasc Pharmacol. 2017;70:255-262.
    PubMed     Abstract available


    July 2017
  41. DE VRIES LJ, Geczy T, Szili-Torok T
    Sleep medications containing melatonin can potentially induce ventricular arrhythmias in structurally normal hearts: a two-patient report.
    J Cardiovasc Pharmacol. 2017 Jul 13. doi: 10.1097/FJC.0000000000000515.
    PubMed     Abstract available


  42. BANOVCIN P JR, Skornova I, Samos M, Schnierer M, et al
    Platelet aggregation in direct oral factor Xa inhibitors-treated patients with atrial fibrillation: a pilot study.
    J Cardiovasc Pharmacol. 2017 Jul 13. doi: 10.1097/FJC.0000000000000516.
    PubMed     Abstract available


  43. ZHONG P, Quan D, Huang Y, Huang H, et al
    CaMKII activation promotes cardiac electrical remodeling and increases the susceptibility to arrhythmia induction in high fat diet-fed mice with hyperlipidemia conditions.
    J Cardiovasc Pharmacol. 2017 Jul 4. doi: 10.1097/FJC.0000000000000512.
    PubMed     Abstract available


    June 2017
  44. BOSSU A, Varkevisser R, Beekman HDM, Houtman MJC, et al
    Short-term Variability of Repolarization Is Superior to Other Repolarization Parameters in the Evaluation of Diverse Antiarrhythmic Interventions in the Chronic Atrioventricular Block Dog.
    J Cardiovasc Pharmacol. 2017;69:398-407.
    PubMed     Abstract available


    May 2017
  45. VECSERNYES M, Szokol M, Bombicz M, Priksz D, et al
    Alpha-Melanocyte-stimulating Hormone Induces Vasodilation and Exerts Cardioprotection Through the Heme-Oxygenase Pathway in Rat Hearts.
    J Cardiovasc Pharmacol. 2017;69:286-297.
    PubMed     Abstract available


    March 2017
  46. LIU Y, Scherlag BJ, Fan Y, Xia W, et al
    Acetylcholine-Atropine Interactions: Paradoxical Effects on Atrial Fibrillation Inducibility.
    J Cardiovasc Pharmacol. 2017 Mar 21. doi: 10.1097/FJC.0000000000000484.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: